Abbott and AtaCor Team Up on New ICD Technology.
In a major step forward for heart health, healthcare leader Abbott has announced a new partnership with AtaCor Medical. Together, they are working on a next-generation “extravascular” defibrillator system.
But what does that actually mean for patients? Let’s break down why this is such a big deal and how it could change the way we treat irregular heart rhythms.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ Abbott and AtaCor Medical Partnership
➜ Medtronic vs Abbott extravascular ICD competition
➜ Benefits of extravascular defibrillators for heart patients
➜ ALARION EV Study clinical trial dates
➜ Abbott and AtaCor Medical Collaboration
Key Takeaways
- The partnership between Abbott and AtaCor Medical aims to develop a next-generation defibrillator that operates entirely outside the heart and blood vessels.
- By placing leads in the rib space rather than through veins, this “extravascular” approach significantly reduces risks like vascular injury, lead fractures, and infections.
- The system combines AtaCor’s specialized Atala™ lead with Abbott’s advanced ICD technology to deliver life-saving shocks and pacing more efficiently.
- A major clinical trial, the ALARION EV Study, is scheduled to begin in 2026 to evaluate the safety and performance of this device in a real-world setting.
- The ultimate goal of this collaboration is to offer a safer, less invasive alternative to traditional heart devices, improving the long-term quality of life for cardiac patients.
What is an EV-ICD?
Most traditional ICDs (Implantable Cardioverter Defibrillators) require wires, called “leads,” to be placed directly into the heart through the blood vessels. While these save lives, they can sometimes cause complications because the wires are inside the heart and veins.
The new EV-ICD (Extravascular ICD) system is different. It is designed to be placed outside the heart and blood vessels. Specifically, the lead is tucked into a space near the breastbone. This “outside-the-heart” approach aims to provide the same life-saving shocks when the heart rhythm goes haywire, but with fewer risks to the patient’s cardiovascular system.
How is this different from a Subcutaneous ICD (S-ICD)?
While both systems avoid the heart’s interior, they aren’t the same. A standard subcutaneous ICD (like Boston Scientific’s S-ICD) sits just under the skin. Because it is further away from the heart, it often requires a larger battery and a more powerful “shock” to work.
The Abbott-AtaCor EV-ICD sits deeper, under the rib cage but still outside the heart. This closer proximity allows the device to be smaller and, most importantly, allows it to provide antitachycardia pacing (ATP), a “gentler” way to fix heart rhythms that traditional subcutaneous devices simply can’t do.
Abbott and AtaCor Medical Partnership
This partnership combines the best of both companies:
- AtaCor Medical provides the specialized lead (called the Atala™ lead) that sits outside the blood vessels.
- Abbott provides the sophisticated ICD system that controls the device and monitors the heart.
This partnership is just one example of how minimally invasive heart procedures are replacing traditional open-heart surgery for better patient outcomes.
By joining forces, the companies hope to create a device that is not only safer to implant but also more efficient at delivering energy to the heart when it’s needed most.
👉 For complete forecasts, procedure volumes, and competitor shares, see iData Cardiovascular Devices Market Insights (complimentary summaries available).
Medtronic vs Abbott extravascular ICD competition
For the last few years, Medtronic has largely held a monopoly on the extravascular market with its Aurora EV-ICD system. While Medtronic was the first to market, the partnership between Abbott and AtaCor is set to provide the first real competition.
This is great news for the healthcare industry; more players in the market usually lead to faster innovation, more choices for doctors, and ultimately, better pricing and access for patients.
Benefits of extravascular defibrillators for heart patients
For many, this technology offers a safer path to recovery, similar to the recent CMS approval for the TriClip system, which expanded access to minimally invasive repair for tricuspid regurgitation patients. It provides the security of a traditional defibrillator without the long-term wear-and-tear risks associated with placing wires inside the heart.
The design also includes advanced pacing capabilities, meaning it can help keep the heart beating at a steady rate more effectively than many existing products.
ALARION EV Study clinical trial dates
We won’t have to wait long to see this technology in action. AtaCor is planning to launch a major clinical trial, called the ALARION EV Study, in 2026. This trial will test the system in real-world scenarios to ensure it is safe and effective before it becomes widely available to the public.
Abbott and AtaCor Medical Collaboration
Abbott continues to be a leader in cardiac rhythm management, and this collaboration with AtaCor shows they are focused on making heart treatments less invasive.
As we look toward 2026, this technology could offer a new lease on life for thousands of patients who need heart monitoring without the complications of traditional surgery.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
